Scientists from the Bing Center for WM published two highly impactful articles in the journal BLOOD, including a Plenary Contribution led by Zachary Hunter and an Original Contribution led by Steve Treon that describe the identification of highly prevalent mutations in the CXCR4 gene. Mutations found in the CXCR4 gene represent the second most common mutations after MYD88 L265P that was previously reported by the Bing Center in the New England Journal of Medicine in 2012 in over 90% of patients with WM.
May 17, 2014, Tampa, Florida: Nearly 300 patients and caregivers were present for the afternoon session in which Dr. Treon discussed the diagnostic and treatment implications of the MYD88 L265P and CXCR4 WHIM mutations that were discovered by the Bing Center for WM, and reported in two publications in BLOOD. Dr. Treon also discussed the results of the clinical trial with ibrutinib in WM patients, and the impact of CXCR4 mutations on response outcome.
The WM Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Plasma cell regulatory pathways in WM. In recent studies, we have attempted to dissect the molecular mechanisms which prevent WM cells from fully differentiating into plasma cells. Ordinarily, B-cells mature in a defined manner passing through the mature B-cell stage to lymphoplasmacytic cells, and then onto mature plasma cells. Mature plasma cells make antibodies that serve to protect us against pathogens, and typically include the IgA and IgG antibodies.